Professor Nigel Minton has previously spent 25 years in the applied environment of the Department of Health Centre for Applied Microbiology and Research (CAMR), Porton. His specialism has been the genus Clostridium from both a medical (infection and anti-cancer spore delivery vehicles) and industrial (chemicals and fuels) perspective. He moved to the University of Nottingham in 2004 to establish the Clostridia Research Group – now the SBRC.
He has an international reputation for excellence in advanced gene technologies, including the ClosTron, the most widely used clostridial mutagen. The portfolio of MTAs dealing with their distribution is the largest at the University. He holds BBSRC partnership awards with China and Brazi, two BBSRC ERANET grants (one as coordinator), funding from the NIH, Innovate_UK and MRC and coordinates a HORIZON 2020 Early Training Network (ETN) for 15 PhD students. He is also the director of the BBSRC Network in Industrial Biotechnology and Bioenergy (NIBB), “C1net: Chemicals from C1 Gas”. He currently works in partnership with, or is directly funded by, more than 10 companies, has an Industrial CASE studentship with DNA2.0 (now ATUM) and is a recent (2015) recipient of a Royal Society Wolfson Research Merit Award. He has an h-index of 46, has filed 22 patents and has secured in excess of £45M in funding since arriving at Nottingham. He sits on the LanzaTech and Manchester SBRC Scientific Advisory Boards.
For further details: Professor Nigel Minton